Volker Soyez
Partner | SGP Schneider Geiwitz & Partner – Wirtschaftsprüfer | Brussels
Getty Inks AI Pact As Regulators Eye $3.7B Shutterstock Deal
Getty Inks AI Pact As Regulators Eye $3.7B Shutterstock Deal By Editorial Team Getty Images announced on Friday that it has entered into a multiyear image licensing agreement with Perplexity, an artificial intelligence-powered search engine company. This development comes amidst ongoing regulatory scrutiny of Getty Images’ proposed $3.7 billion merger with Shutterstock. The agreement with […]
Sandisk Urges Federal Circuit to Address ‘Settled Expectations’ Issue
Sandisk Urges Federal Circuit to Address ‘Settled Expectations’ Issue By Editorial Team Sandisk Technologies Inc. has reiterated its stance to the Federal Circuit, emphasizing that the U.S. Patent and Trademark Office’s refusal of patent reviews based on an owner’s “settled expectations” violates the law. The company asserts that immediate court action is necessary, as most […]
Squires’ National Security Fears Over RPIs Draw Skepticism
Squires’ National Security Fears Over RPIs Draw Skepticism By Editorial Team U.S. Patent and Trademark Office Director John Squires has initiated a policy requiring patent challengers to disclose all real parties in interest when filing initial Patent Trial and Appeal Board petitions. This move is part of Squires’ efforts to restrict challenges and is motivated […]
Wheeling & Appealing: The Latest Must-Know Appellate Action
Wheeling & Appealing: The Latest Must-Know Appellate Action By Editorial Team Law360 recently reported on significant appellate arguments set for November, including a high-profile case involving a lawsuit from President Donald Trump against Hillary Clinton’s lawyer at Williams & Connolly. The legal calendar also features disputes on New York City housing, drug pricing, immigrant rights, […]
Wheeling & Appealing: The Latest Must-Know Appellate Action
Wheeling & Appealing: The Latest Must-Know Appellate Action By Editorial Team As the legal landscape continues to evolve, a myriad of appellate actions are making headlines. From high-profile cases involving the 2016 presidential election to issues surrounding New York City housing, drug prices, immigrant rights, and laws targeting “patent trolls,” the appellate docket is diverse […]
Amgen Files Lawsuit Challenging Colorado Price Cap for Arthritis Drug
Amgen Files Lawsuit Challenging Colorado Price Cap for Arthritis Drug By Editorial Team Amgen has once again taken legal action against Colorado over its price cap for the arthritis drug Enbrel. The pharmaceutical company claims that Colorado’s drug price-control statute violates the U.S. Constitution, conflicts with federal patent law, and poses a threat to patients’ […]
You must be logged in to post a comment.